vs
Side-by-side financial comparison of DOMO, INC. (DOMO) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
IOVANCE BIOTHERAPEUTICS, INC. is the larger business by last-quarter revenue ($86.8M vs $79.4M, roughly 1.1× DOMO, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs -0.5%). DOMO, INC. produced more free cash flow last quarter ($1.1M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs -0.5%).
Domo, Inc. is an American cloud software company based in American Fork, Utah, United States. It specializes in artificial intelligence, business intelligence, and data visualization and is designed to provide real-time access to business data for decision makers across the company with minimal IT involvement. It is a Software-as-a-Service (SaaS) venture.
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
DOMO vs IOVA — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $79.4M | $86.8M |
| Net Profit | $-10.4M | — |
| Gross Margin | 74.2% | 67.4% |
| Operating Margin | -8.7% | -84.7% |
| Net Margin | -13.1% | — |
| Revenue YoY | -0.5% | 17.7% |
| Net Profit YoY | 44.6% | — |
| EPS (diluted) | $-0.25 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $79.4M | $86.8M | ||
| Q3 25 | $79.7M | $67.5M | ||
| Q2 25 | $80.1M | $60.0M | ||
| Q1 25 | $78.8M | $49.3M | ||
| Q4 24 | $79.8M | $73.7M | ||
| Q3 24 | $78.4M | $58.6M | ||
| Q2 24 | $80.1M | $31.1M | ||
| Q1 24 | $80.2M | $715.0K |
| Q4 25 | $-10.4M | — | ||
| Q3 25 | $-22.9M | $-91.3M | ||
| Q2 25 | $-18.1M | $-111.7M | ||
| Q1 25 | $-17.7M | $-116.2M | ||
| Q4 24 | $-18.8M | — | ||
| Q3 24 | $-19.5M | $-83.5M | ||
| Q2 24 | $-26.0M | $-97.1M | ||
| Q1 24 | $-18.7M | $-113.0M |
| Q4 25 | 74.2% | 67.4% | ||
| Q3 25 | 74.8% | 43.0% | ||
| Q2 25 | 74.2% | 5.5% | ||
| Q1 25 | 74.4% | -0.8% | ||
| Q4 24 | 75.0% | 68.7% | ||
| Q3 24 | 74.3% | 46.2% | ||
| Q2 24 | 74.1% | -0.8% | ||
| Q1 24 | 76.3% | — |
| Q4 25 | -8.7% | -84.7% | ||
| Q3 25 | -9.1% | -140.7% | ||
| Q2 25 | -17.9% | -189.8% | ||
| Q1 25 | -15.6% | -245.8% | ||
| Q4 24 | -13.9% | -117.5% | ||
| Q3 24 | -18.5% | -152.1% | ||
| Q2 24 | -26.8% | -327.6% | ||
| Q1 24 | -16.6% | -16464.6% |
| Q4 25 | -13.1% | — | ||
| Q3 25 | -28.8% | -135.3% | ||
| Q2 25 | -22.5% | -186.2% | ||
| Q1 25 | -22.4% | -235.5% | ||
| Q4 24 | -23.5% | — | ||
| Q3 24 | -24.9% | -142.7% | ||
| Q2 24 | -32.5% | -312.2% | ||
| Q1 24 | -23.3% | -15800.8% |
| Q4 25 | $-0.25 | — | ||
| Q3 25 | $-0.56 | — | ||
| Q2 25 | $-0.45 | $-0.33 | ||
| Q1 25 | $-0.45 | $-0.36 | ||
| Q4 24 | $-0.48 | $-0.24 | ||
| Q3 24 | $-0.51 | $-0.28 | ||
| Q2 24 | $-0.69 | $-0.34 | ||
| Q1 24 | $-0.51 | $-0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $297.0M |
| Total DebtLower is stronger | $124.2M | — |
| Stockholders' EquityBook value | $-191.9M | $698.6M |
| Total Assets | $201.6M | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $297.0M | ||
| Q3 25 | — | $300.8M | ||
| Q2 25 | $47.2M | $301.2M | ||
| Q1 25 | $45.3M | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | — | $397.5M | ||
| Q2 24 | $61.2M | $412.5M | ||
| Q1 24 | $60.9M | $356.2M |
| Q4 25 | $124.2M | — | ||
| Q3 25 | $121.9M | — | ||
| Q2 25 | $119.7M | — | ||
| Q1 25 | $117.7M | — | ||
| Q4 24 | $115.6M | — | ||
| Q3 24 | $115.2M | — | ||
| Q2 24 | $114.1M | — | ||
| Q1 24 | $113.5M | — |
| Q4 25 | $-191.9M | $698.6M | ||
| Q3 25 | $-191.5M | $702.3M | ||
| Q2 25 | $-178.7M | $698.5M | ||
| Q1 25 | $-177.2M | $767.9M | ||
| Q4 24 | $-171.2M | $710.4M | ||
| Q3 24 | $-166.4M | $773.5M | ||
| Q2 24 | $-163.5M | $768.5M | ||
| Q1 24 | $-153.5M | $680.0M |
| Q4 25 | $201.6M | $913.2M | ||
| Q3 25 | $195.7M | $904.9M | ||
| Q2 25 | $189.7M | $907.4M | ||
| Q1 25 | $214.3M | $966.7M | ||
| Q4 24 | $190.2M | $910.4M | ||
| Q3 24 | $197.8M | $991.1M | ||
| Q2 24 | $204.4M | $964.3M | ||
| Q1 24 | $225.7M | $869.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.4M | $-52.6M |
| Free Cash FlowOCF − Capex | $1.1M | $-61.9M |
| FCF MarginFCF / Revenue | 1.4% | -71.3% |
| Capex IntensityCapex / Revenue | 2.9% | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $9.9M | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $3.4M | $-52.6M | ||
| Q3 25 | $3.4M | $-78.7M | ||
| Q2 25 | $4.0M | $-67.4M | ||
| Q1 25 | $8.9M | $-103.7M | ||
| Q4 24 | $-13.7M | $-73.3M | ||
| Q3 24 | $-6.2M | $-59.0M | ||
| Q2 24 | $1.9M | $-98.4M | ||
| Q1 24 | $5.4M | $-122.3M |
| Q4 25 | $1.1M | $-61.9M | ||
| Q3 25 | $1.0M | $-89.5M | ||
| Q2 25 | $1.0M | $-74.9M | ||
| Q1 25 | $6.7M | $-109.9M | ||
| Q4 24 | $-16.2M | $-77.5M | ||
| Q3 24 | $-8.4M | $-61.3M | ||
| Q2 24 | $-625.0K | $-98.9M | ||
| Q1 24 | $2.9M | $-126.5M |
| Q4 25 | 1.4% | -71.3% | ||
| Q3 25 | 1.3% | -132.7% | ||
| Q2 25 | 1.3% | -124.9% | ||
| Q1 25 | 8.5% | -222.8% | ||
| Q4 24 | -20.3% | -105.1% | ||
| Q3 24 | -10.7% | -104.6% | ||
| Q2 24 | -0.8% | -317.9% | ||
| Q1 24 | 3.6% | -17685.3% |
| Q4 25 | 2.9% | 10.7% | ||
| Q3 25 | 2.9% | 16.1% | ||
| Q2 25 | 3.7% | 12.4% | ||
| Q1 25 | 2.8% | 12.6% | ||
| Q4 24 | 3.2% | 5.7% | ||
| Q3 24 | 2.8% | 3.9% | ||
| Q2 24 | 3.2% | 1.4% | ||
| Q1 24 | 3.1% | 583.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOMO
| Subscription | $71.9M | 91% |
| Professional Servicesand Other | $7.5M | 9% |
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
